Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis

Rayes, Hanan Al; Alazmi, Mansour; Attar, Suzan M.; Alderaan, Khaled; Alghamdi, Mushabab; Alghanim, N.; Alhazmi, Ahmed Ali; Alkhadhrawi, Nadeer; Almohideb, Mohammad; Alzahrani, Zeyad; Bedaiwi, Mohamed; Halabi, Hussein

doi:10.1007/s00296-021-05029-5

Cited by 5 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, our consensus statements are aligned with the most recently published Saudi consensus recommendations. 106 Our detailed consensus recommendations can help physicians and healthcare professionals in the UAE to make informed treatment decisions, improvise treatment strategies, monitor therapies, as well as effectively manage comorbidities in patients with PsA.…”

Section: Discussionmentioning

confidence: 99%

Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates

et al. 2022

View full text Add to dashboard Cite

Objective: Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by heterogeneous clinical manifestations, substantially impacts the quality of life of affected individuals. This article aims at developing consensus recommendations for the management of PsA and associated comorbidities and screening and monitoring requirements of PsA therapies in the United Arab Emirates (UAE) population.Methods: An extensive review of present international and regional guidelines and publications on the pharmacological management, monitoring of therapies in the context of PsA was performed. Key findings from guidelines and literature were reviewed by a panel of experts from the UAE at several meetings to align with current clinical practices. Consensus statements were formulated based on collective agreement of the experts and members of Emirates Society for Rheumatology. Results:The consensus recommendations were developed to aid practitioners in clinical decision-making with respect to dosage recommendations for pharmacological therapies for PsA, including conventional drugs, non-biologic, and biologic therapies.Consensus recommendations for therapeutic options for the treatment of PsA domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease, were developed. The panel emphasized the importance of monitoring PsA therapies and arrived at a consensus on monitoring requirements for PsA therapies. The expert panel proposed recommendations for the management of common comorbidities associated with PsA. Conclusion:These consensus recommendations can guide physicians and healthcare professionals in the UAE in making proper treatment decisions, as well as efficiently managing comorbidities and monitoring therapies in patients with PsA.

show abstract

Section: Discussionmentioning

confidence: 99%

Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As a result, there is often a debate among healthcare providers about how to make clinical decisions when managing the disease, which can result in either over-prescribing or under-prescribing biological agents. Al Rayes, et al’s recently published consensus-based recommendations addressed the aspects of diagnosis, referral and clinical management of patients with PSA [ 20 ]. Therefore, this paper aims to deliver evidence-based consensus recommendations for the optimal use and monitoring of biological therapy in managing PsA.…”

Section: Introductionmentioning

confidence: 99%

The Saudi consensus recommendations for the management of psoriatic arthritis (2023)

Al-Homood,

Al Ghanim,

Fatani

et al. 2024

Clin Rheumatol

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a complex inflammatory disease characterized by musculoskeletal and non-musculoskeletal manifestations. It is a distinct disease entity at the interface between rheumatology and dermatology, making it challenging to manage. The diverse clinical presentation and severity of PsA require a multidisciplinary approach for optimal care. Early diagnosis and management are necessary to improving quality of life for patients. In Saudi Arabia, there is currently no unified national consensus on the best practices for managing PsA. This lack of consensus leads to debate and uncertainty in the treatment of the disease, resulting in over or under prescribing of biological agents. To address this issue, a multidisciplinary work group was formed by the Saudi Ministry of Health. This group, consisting of dermatologists, rheumatologists, and pharmacists, aimed to develop evidence-based consensus recommendations for he use and monitoring of biological therapy in PsA management. The work group conducted five consensus workshops between December 2021 to March 2022. Using the nominal group technique, they discussed various aspects of PsA management, including eligibility criteria for biological treatment, monitoring of disease activity, treatment goals, screening, precautions, and management of PsA with biologic therapies. The group also considered special considerations for patients with comorbidities, pregnant and lactating women, as well as pediatric and adolescent populations. The resulting consensus document provides recommendations that are applicable to the Saudi setting, taking into account international guidelines and the specific needs of PsA patients in the country. The consensus document will be regularly updated to incorporate new data and therapeutic agents as they become available. Key Points• In Saudi Arabia, there is a lack of unified national consensus on the optimal management of PsA, therefore, this article aims to provide up-to-date evidence-based consensus recommendations for the optimal use and monitoring of biologic therapy in the management of PsA in Saudi Arabia.• The consensus development process was undertaken by a multidisciplinary work group of 13 experts, including two dermatologists, six rheumatologists, and five pharmacists.• There is more than one disease activity tool used in PsA disease, depending on the disease domain – peripheral arthritis Disease Activity Index in Psoriatic Arthritis (DAPSA) or Minimal Disease Activity (MDA), axial PsA Ankylosing Spondylitis Disease Activity Score (ASDAS), and dactylitis and enthesitis MDA.• The main goal of therapy in all patients with PsA is to achieve the target of remission, or alternatively, low disease activity in all disease domains and improve quality of life (QoL).

show abstract

Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology–Rheumatology clinic: a retrospective real-world study

et al. 2022

View full text Add to dashboard Cite

Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis

Cited by 5 publications

References 83 publications

Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates

Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates

The Saudi consensus recommendations for the management of psoriatic arthritis (2023)

Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology–Rheumatology clinic: a retrospective real-world study

Contact Info

Product

Resources

About